Baudax Bio Announces Clinical Program Update for Neuromuscular Blocking Agents BX-1000, BX-2000 and BX-3000
MALVERN, PA — Baudax Bio, Inc. (NASDAQ: BXRX) this week announced a clinical program update for its neuromuscular blocking agents (NMBs), including completion of a dose-escalation study evaluating BX-1000 in …
Baudax Bio Announces Clinical Program Update for Neuromuscular Blocking Agents BX-1000, BX-2000 and BX-3000 Read More